Clinical Trial Detail

NCT ID NCT02495636
Title Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Yale University
Indications

lung non-small cell carcinoma

Therapies

Atezolizumab + DEC-205-NY-ESO-1 fusion protein vaccine

Age Groups: adult

Additional content available in CKB BOOST